Jonathan Strickler, MD

Presentation(s):

• LBA-2: MOUNTAINEER: Open-label, phase 2 study of tucatinib in combination with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017)

  Saturday, July 2, 2022
  12:35 – 12:47

• Clinical Evolution of Targeted Treatments for HER2+ mCRC Patients

  Saturday, July 2, 2022
  14:10 – 14:25

• Panel Discussion and Interactive Q&A

  Saturday, July 2, 2022
  14:25 – 14:55